Tablet Covid vaccine maker to push on with clinical trials

Despite lackluster results from an early trial of its tablet Covid-19 vaccine, Vaxart Inc. said Thursday that it will move forward to a midstage study by the end of June. The small South San Francisco company (NASDAQ: VXRT) said it is driven by the emergence of new strains of Covid that some injectable vaccines may not cover well and slow progress in reaching people with needle jabs before new strains emerge. "A better solution is needed given that Covid-19 may be a challenge for years to come,"…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news